In an ocean of technical advances, a one-stop software shop, offering a fully customised, device-agnostic practice management system to ophthalmology clinics, was described as a technology breakthrough at RANZCO 2024. “GoodX brings a different software package to New Zealand, which no one else seems
US researchers have found that deleting a gene in mice reduced the subretinal fibrosis associated with nAMD, indicating a new therapeutic target to treat the nearly two-thirds of nAMD patients for whom anti-VEGF treatment is ineffective.
Preliminary results of a clinical trial of MyopiaX, a low-level laser device to treat progressive myopia in children, showed it was safe and tolerable and produced proof-of-concept data, reported its German developer Dopavision.
The authors of a University of Auckland study investigating the safety of UVC light to treat microbial keratitis said evidence of DNA damage was limited to the superficial epithelium. The study, led
University of East Anglia (UEA) researchers have made a breakthrough in ocular device technology with the introduction of a novel resin to 3D-print intraocular lenses (IOLs), potentially offering cheaper, faster manufacturing and more customisation.
Interim results from the ongoing phase 2 Australian trial of darovasertib, an oral neoadjuvant/adjuvant uveal melanoma (UM) treatment, showed 75% of treated patients were spared enucleation, reported the drug’s US developer, Ideaya Biosciences.
New to this part of the world, Vitrocap N is a nutritional supplement that’s been specially formulated for eye floaters...
MDNZ has launched a new online referral tool to make it easier for ECPs to refer their macular degeneration patients.
US researchers have described a type of neuron which guides the formation of the retina’s lattice of blood vessels which could unlock new therapeutic routes for diseases related to impaired blood flow
A UK poll has revealed a third (32%) of people who had an eye condition in the last five years approached their GP first, with another third (31%) choosing healthcare routes other than optometrists.
US researchers found melatonin use was associated with a reduced risk of both diagnosis and progression of AMD in a large study of patients over the age of 50 years. Led by researchers at Case
A US study found the SARS-CoV-2 (Covid-19) virus is not only capable of penetrating both the retinal pigment epithelium (RPE) and the retinal vascular endothelium (RvEC) but also triggered a “signific
